Molecule Generator Articles & Analysis
10 news found
“The mechanism of action of ATG-037 in inhibiting adenosine-generating CD73 is expected to reverse an immunosuppressed tumor microenvironment, thereby creating potential additive benefit with multiple immuno-oncological approaches. ...
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first-next generation single-molecule protein sequencing platform, today announced that it will be participating in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ...
Key Takeaways: Next-generation single-molecule protein sequencing technology is poised to transform the science and research community’s understanding of the proteome by unlocking unprecedented insights about the human body - just as the advent of next-generation DNA sequencing has revolutionized our knowledge of the human genome over ...
The funds awarded to Orbit will further validate the microfluidic components of Orbit’s peptide discovery platform, resulting in a next-generation microfluidic-based functional screen capable of interrogating millions of peptides in cell-based assays. ...
Insilico's PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico's AI platform. The compound can be efficiently prepared with a two-step synthesis from commercial starting materials. ...
"Powered by AI, the MAT2A program team was able to discover the PCC molecule with high selectivity of MTAP-deleted cancer cells over wide-type cells, which we believe provides key differentiation compared to reported MAT2A inhibitors," said Feng Ren, PhD, Chief Scientific Officer of Insilico Medicine. "This is the second PCC in our growing synthetic lethality pipeline, and we are ...
ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine's end-to-end AI-powered drug discovery platform. ...
Other highlights include: Advancing four AI-discovered programs to the clinic while further growing clinical development capabilities Expanding the AI Workbench from rare, monogenic conditions to more complex, common diseases Generating a large-scale set of opportunities by evaluating one hundred genes to identify novel targets, mechanisms, and preclinical programs that ...
Sibylla PPI-FIT technology identifies novel druggable pockets in the intermediate folding states of proteins Sibylla intends to market the PPI-FIT technology platform-as-a-service‚ to the biotechnology and pharmaceutical industries. It also plans to generate its own in-house proprietary pipeline Verona (Italy), May 18th 2021 – Sibylla Biotech announced a research ...
Last September Insilico Medicine published a landmark paper in Nature Biotechnology demonstrating the application of its generative tensorial reinforcement learning systems to generate novel molecules for kinases in just 46 days including experimental validation which was widely covered by the press. ...